Compare
Intensity Therapeutics, Inc. vs MiNK Therapeutics, Inc. vs BioAtla, Inc. vs Entera Bio Ltd.
| Latest fiscal year | Intensity Therapeutics, Inc. INTS | MiNK Therapeutics, Inc. INKT | BioAtla, Inc. BCAB | Entera Bio Ltd. ENTX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | $42.0K |
| Revenue growth (YoY) | n/a | n/a | n/a | -76.8% |
| Gross margin | n/a | n/a | n/a | 0.0% |
| Operating margin | n/a | n/a | n/a | n/m |
| Net margin | n/a | n/a | n/a | n/m |
| Net income | -$11.61M | -$12.49M | -$59.61M | -$11.44M |
| EPS (Diluted) | -$8.56 | -$2.93 | -$1.01 | $0.25 |
| Operating cash flow | -$9.23M | -$5.93M | -$48.20M | -$7.37M |
| Free cash flow | n/a | n/a | n/a | -$7.48M |
| Cash & equivalents | $11.92M | $13.36M | $7.12M | $7.11M |
| Total assets | $14.10M | $14.24M | $13.83M | $15.99M |
| Total liabilities | $2.23M | n/a | $50.02M | $2.89M |
| Shareholders' equity | $11.88M | -$14.23M | $36.19M | $13.10M |
| Return on year-end equity | -97.7% | n/a | -164.7% | -87.3% |
| Shares outstanding | 2.52M | n/a | 63.46M | 46.18M |
Revenue, most recent five fiscal years
| Fiscal year | Intensity Therapeutics, Inc. | MiNK Therapeutics, Inc. | BioAtla, Inc. | Entera Bio Ltd. |
|---|---|---|---|---|
| Latest | n/a | n/a | $300.0K Ended 2021-12-31 | $42.0K Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | n/a | $181.0K Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | n/a | $0 Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | n/a | $134.0K Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | $571.0K Ended 2021-12-31 |